Quarterly report pursuant to Section 13 or 15(d)

Revenue from Contracts with Customers (Details)

v3.19.1
Revenue from Contracts with Customers (Details) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Disaggregation of Revenue [Line Items]    
Total revenue $ 5,411,443 $ 4,482,775
Prescribed dietary supplements    
Disaggregation of Revenue [Line Items]    
Total revenue 1,791,000 2,231,000
Prescription drugs    
Disaggregation of Revenue [Line Items]    
Total revenue 3,620,000 2,029,000
Sales force revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 0 $ 222,656
Customer Concentration Risk | Sales Revenue, Net | Major Customer Number One    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 35.00%  
Customer Concentration Risk | Sales Revenue, Net | Major Customer Number Two    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 33.00%  
Customer Concentration Risk | Sales Revenue, Net | Major Customer Number Three    
Disaggregation of Revenue [Line Items]    
Concentration risk percentage 25.00%